Bavarian Nordic has established a well respected position in the
biodefense space and is further utilizing its core competencies
with respect to developing and producing viral vaccine platforms
(MVA-BN® and other poxvirus-vectors) for a wide variety of
applications in biotechnology and medicine.
The company designs, constructs, develops and manufactures viral
vaccines for research, clinical and commercial applications.
Our regulatory and clinical development teams have broad
competencies in designing and implementing clinical
programs for therapeutic and prophylactic vaccines covering
smallpox, prostate cancer, breast cancer and RSV.
Bavarian Nordic's manufacturing facility in Denmark is the
world's only dedicated facility for the industrial manufacturing of
MVA-based vaccines. The facility has been designed and constructed
to fulfil the strictest European and US requirements for the
production of sterile vaccines.
We have worked with the U.S. Government in the field of
smallpox for over 10 years. In June 2007, the U.S. Government
solidified this partnership by awarding Bavarian Nordic a 5-year
contract (RFP-3) to deliver 20 million doses of an MVA-based,
non-replicating smallpox vaccine, IMVAMUNE®.
Bavarian Nordic is cooperating with other government agencies
around the world in the biodefense space.